Scientists hunt for immune clues in glioblastoma patients
NCT ID NCT04657146
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects blood and bone marrow samples from 40 adults with newly diagnosed glioblastoma to track changes in immune cells over time. Researchers aim to understand how the immune system responds to the tumor and standard treatments. The goal is to gather foundational data that could lead to new immunotherapy strategies for this aggressive brain cancer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could provide foundational data to develop new immunotherapy approaches for glioblastoma.
- What could go wrong
- This is an observational study that does not test a treatment, so it will not directly benefit participants. The study is currently suspended, and results may not lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients meeting the terms of the inclusion and exclusion criteria above will be eligible to participate in the study. This includes all patients over 18 years of age, both sexes, and all minorities. A total of 40 patients will be enrolled in the study. Patients who are not confirmed to have GBM on histopathological analysis, or who do not qualify as gross total resection per the definition above will be removed from the study and replaced until a total of 40 patients is reached.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years of age. * Suspected newly-diagnosed GBM, World Health Organization (WHO) Grade IV with intent for gross total resection (as defined above). * Accessibility for treatment and follow up. * Patient consent obtained according to Duke institutional policy. * Women of child bearing potential (WOCBP) must have a negative serum pregnancy test according to standard of care prior to surgery. Exclusion Criteria: * Patients who previously received other conventional therapeutic interventions for newly diagnosed glioblastoma with the exception of surgical intervention. * Patients with prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin * Pregnant or breast-feeding during the study period. * Patients with an active infection, or febrile within 24 hours of surgery. * Patients with inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, or other autoimmune disease. * Patients with history of or active hematologic or bone marrow diseases, including but not limited to diagnosed lymphomas, leukemias, sickle cell or other anemias not associated with their current condition or polycythemia vera. * Prior bone marrow harvests preceding this study. * Patients with known or suspected immunodeficiency or human immunodeficiency virus (HIV). * Hematocrit \< 24 % pre-operatively. * Patients with a serious active infection or other serious underlying medical conditions that would impair the ability of the patient to receive protocol treatment or comply with protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glioblastoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer lights up Oxygen-Starved brain tumors
- Can a common virus vaccine help fight brain cancer?
- Radioactive tiles target brain tumors in frail patients
- Breathing CO2 during brain scans could reveal hidden tumor disruption
- Can an oral drug that starves tumors help Hard-to-Treat cancers?
- Can repeated MRI scans reveal how tumors respond to radiation?